The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report

An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report

February 8, 2022 • By Residents from the RheumMadness Leadership Team: Michael Macklin, MD, PharmD; Ben Kellogg, MD; Lauren He, MD; & David Leverenz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Last year’s RheumMadness winner, avacopan, was approved by the U.S. Food & Drug Administration just a few months after the tournament ended. Pim Kinases could certainly win this year’s tournament, but fans may have to wait a bit longer for FDA approval.

You Might Also Like
  • Targeting Disease-Causing Cells: RheumMadness 2022 Chimeric Antigen Receptor T Cells Scouting Report
  • Conversation: RheumMadness 2022 Reproductive Health Guide Scouting Report
  • Regeneration: RheumMadness 2022 Axolotl Limbs Scouting Report
Explore This Issue
May 2022

Michael Macklin, MD, PharmD, is an internal medicine resident at the University of Pittsburgh Medical Center.

 

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Ben Kellogg, MD, is an internal medicine resident at Duke University School of Medicine, Durham, N.C. 

Lauren He, MD, is an internal medicine resident at the University of Chicago School of Medicine. 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

David Leverenz, MD, is an assistant professor of medicine in the Division of Rheumatology and Immunology at Duke University Medical School, Durham, N.C.

References

  1. Maney NJ, Lemos H, Barron‐Millar B, et al. PIM kinases as therapeutic targets in early rheumatoid arthritis. Arthritis Rheumatol. 2021 Oct;73(10):1820–1830.
  2. Ha Y, Choi YS, Han DW et al. PIM-1kinase is a novel regulator of proinflammatory cytoikine-mediated responses in rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology (Oxford). 2019 Jan 1;58(1):154–164.
  3. Ytterberg S, Bhatt D, Mikuls T, et al. Safety and efficacy of tofacitinib vs. TNF inhibitors in RA patients aged 50 years or older with one or more cardiovascular risks: Results from a phase 3b/4 randomized safety trial [abstract 0831]. Arthritis Rheumatol. 2021 Oct;73 (suppl 10).
  4. Humby F, Durez P, Buch MH, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021 Jan 23;397(10271):305–317.
  5. Vanderbilt University Medical Center Rheumatology Fellowship. Synovial B cells and therapy response (R4RA) scouting report. 2021 Mar 15.

Experience All of RheumMadness

During RheumMadness, rheumatology concepts represent teams that compete against each other in a tournament, much like basketball teams do in the NCAA’s March Madness tournament. In a series for The Rheumatologist, readers will get a chance to read the scouting reports. Check out the reports from each region:

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Region: Cells

• Anti-NET Antibodies

• Cytokine Networks

• CAR-T Cells

• Pim Kinases

Region: Animal House

• Axolotl Limbs

• Dinosaur SpA

• Dalmatian Urate

• Dog Osteoarthritis

Region: Machines

• AI: JIA Subtypes

• AI: TNFi Response

• DECT in Gout

• PET in LVV

Region: People

• Reproductive Health Guide

• TNFi in Cord Blood

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Research Reviews, Rheumatoid Arthritis Tagged With: cells, Pim kinase, Rheumatoid Arthritis (RA), RheumMadnessIssue: May 2022

You Might Also Like:
  • Targeting Disease-Causing Cells: RheumMadness 2022 Chimeric Antigen Receptor T Cells Scouting Report
  • Conversation: RheumMadness 2022 Reproductive Health Guide Scouting Report
  • Regeneration: RheumMadness 2022 Axolotl Limbs Scouting Report
  • Back to Basics: RheumMadness 2022 Increasing ANA Positivity Scouting Report

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)